Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma.
Humans
Carcinoma, Renal Cell
/ genetics
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
/ genetics
Kidney Neoplasms
/ genetics
Middle Aged
Male
Female
Prognosis
Gene Rearrangement
Adult
Aged
Retrospective Studies
Neoplasm Recurrence, Local
/ genetics
Survival Rate
Immunohistochemistry
In Situ Hybridization, Fluorescence
Fluorescence in situ hybridization
Prognosis
Renal cell carcinoma
TFE3
TFE3-rearranged-RCC
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
06
05
2024
accepted:
19
09
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
To investigate the impact of TFE3 rearrangement, analyzing clinicopathological features that influence renal cell carcinoma (RCC) recurrence, and clarify the role of immunohistochemistry (IHC) staining in diagnosis. We screened patients diagnosed of clear cell RCC (ccRCC), fluorescence in situ hybridization (FISH) was performed on all TFE3 positive IHC tumors. Clinicopathological and survival features were collected for analysis. Out of 695 patients treated for renal tumors, 478 (68.7%) were ccRCC and 22 were suspected of TFE3 rearrangement based on IHC. Subsequent testing revealed 8 (1.15%) were positive in the FISH test (TFE3-rearranged-RCC) and 14 (2.01%) tested negative. No significant differences were noted in general characteristics among the three groups, except for age, TFE3-rearranged-RCC were younger than ccRCC (median age, 49 vs. 58 years, p=0.02). TFE3-rearranged-RCC exhibited a significant higher recurrence rate compared to ccRCC (50% vs 18.8%) and multivariate analysis revealed that TFE3 rearrangement, along with tumor size and metastasis, was an independent prognostic factor for recurrence (HR=4.6; 95% CI 1.1-21.2; p=0.05). Survival analysis demonstrated a significant shorter PFS (progression-free survival) for TFE3-rearranged-RCC compared to ccRCC. TFE3 rearrangement is an independent prognostic factor for recurrence and contributes to a worse PFS, suggesting the necessity of careful follow-up. Diagnosis should be confirmed using FISH due to low specificity of IHC. Further studies are needed to confirm TFE3 IHC staining as a prognostic factor.
Identifiants
pubmed: 39470841
doi: 10.1007/s00345-024-05290-w
pii: 10.1007/s00345-024-05290-w
doi:
Substances chimiques
TFE3 protein, human
0
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
603Informations de copyright
© 2024. The Author(s).
Références
Am J Surg Pathol. 2012 May;36(5):663-70
pubmed: 22498819
BMC Urol. 2022 Jul 18;22(1):109
pubmed: 35850864
Int J Clin Exp Pathol. 2013 Dec 15;7(1):236-45
pubmed: 24427344
Heliyon. 2023 May 06;9(5):e16076
pubmed: 37215783
J Clin Pathol. 2021 May;74(5):291-299
pubmed: 33514585
Am J Clin Pathol. 2023 Dec 1;160(6):549-554
pubmed: 37499055
Front Oncol. 2022 Oct 06;12:1017425
pubmed: 36276115
Eur Urol. 2022 Nov;82(5):458-468
pubmed: 35853783
BMC Urol. 2016 Jul 11;16(1):40
pubmed: 27401463
Semin Diagn Pathol. 2015 Mar;32(2):103-13
pubmed: 25758327
Am J Surg Pathol. 2013 Aug;37(8):1150-63
pubmed: 23715164
Am J Clin Pathol. 2012 May;137(5):761-8
pubmed: 22523215
Front Oncol. 2023 Feb 03;13:1116648
pubmed: 36816933
Springerplus. 2014 May 13;3:245
pubmed: 24877033
Mod Pathol. 2019 May;32(5):710-716
pubmed: 30622287
Cancers (Basel). 2017 Aug 29;9(9):
pubmed: 28850056
Pathol Oncol Res. 2021 Mar 30;27:610360
pubmed: 34257577
BMC Cancer. 2019 Sep 13;19(1):917
pubmed: 31519159